Literature DB >> 2665244

Interactions between dopamine and 5-HT3 receptors suggest new treatments for psychosis and drug addiction.

M D Tricklebank.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2665244     DOI： 10.1016/0165-6147(89)90157-0

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN： 0165-6147            Impact factor:   14.819


× No keyword cloud information.
  10 in total

1.  Diltiazem causes open channel block of recombinant 5-HT3 receptors.

Authors:  M J Gunthorpe; S C Lummis
Journal:  J Physiol       Date:  1999-09-15       Impact factor: 5.182

2.  Further characterization, by use of tryptamine and benzamide derivatives, of the putative 5-HT4 receptor mediating tachycardia in the pig.

Authors:  C M Villalón; M O den Boer; J P Heiligers; P R Saxena
Journal:  Br J Pharmacol       Date:  1991-01       Impact factor: 8.739

3.  Effects of chronic administration of ondansetron (GR38032F), a selective 5-HT3 receptor antagonist, on monoamine metabolism in mesolimbic and nigrostriatal dopaminergic neurons and on striatal D2-receptor binding.

Authors:  M Koulu; J Lappalainen; J Hietala; B Sjöholm
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

4.  The effects of BRL 46470A, a novel 5-HT3 receptor antagonist, and lorazepam on psychometric performance and the EEG.

Authors:  C G Link; T J Leigh; J K Dennison
Journal:  Br J Clin Pharmacol       Date:  1993-04       Impact factor: 4.335

5.  From mouse to man: the 5-HT3 receptor modulates physical dependence on opioid narcotics.

Authors:  Larry F Chu; De-Yong Liang; Xiangqi Li; Peyman Sahbaie; Nicole D'arcy; Guochun Liao; Gary Peltz; J David Clark
Journal:  Pharmacogenet Genomics       Date:  2009-03       Impact factor: 2.089

6.  5HT3 receptor antagonists do not block nicotine induced hyperactivity in rats.

Authors:  B Arnold; K Allison; S Ivanová; P R Paetsch; T Paslawski; A J Greenshaw
Journal:  Psychopharmacology (Berl)       Date:  1995-05       Impact factor: 4.530

7.  The interaction of RS 25259-197, a potent and selective antagonist, with 5-HT3 receptors, in vitro.

Authors:  E H Wong; R Clark; E Leung; D Loury; D W Bonhaus; L Jakeman; H Parnes; R L Whiting; R M Eglen
Journal:  Br J Pharmacol       Date:  1995-02       Impact factor: 8.739

8.  Alleviating symptoms of withdrawal from an opioid.

Authors:  Judith H Wakim
Journal:  Pain Ther       Date:  2012-09-20

9.  Selective catecholamine detection in living cells by a copper-mediated oxidative bond cleavage.

Authors:  Ka Yan Tong; Jia Zhao; Chun-Wai Tse; Pui-Ki Wan; Jianhui Rong; Ho Yu Au-Yeung
Journal:  Chem Sci       Date:  2019-08-14       Impact factor: 9.825

10.  Vortioxetine vs. Other Antidepressants in Patients with Major Depressive Episode With or Without Substance Use Disorder.

Authors:  Georgios D Kotzalidis; Ginevra Lombardozzi; Marta Matrone; Emanuela Amici; Filippo Perrini; Ilaria Cuomo; Sergio De Filippis
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.708
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.